Reiff S, et al. – Using data from the Maltese national electronic database for diabetes treatment in April 2014, researchers compared all-cause 3-year mortality rates among patients on sulphonylurea monotherapy with patients on metformin monotherapy, after adjustment for potential confounders. For this investigation, patients on metformin or sulphonylurea monotherapy were identified and linked to the national mortality database and the laboratory information system. In April 2014, there were 25,792 people on diabetes treatment. During this period there were 2,518 deaths (9.76%), resulting in an average of 32.5 deaths per 1,000 diabetes patients. After adjusting for potential confounders, sulphonylurea monotherapy was correlated with higher all-cause mortality vs metformin monotherapy.